NCT03966105 is a clinical trial of HE and Congo red staining in Wild-type Transthyretin Amyloidosis, sponsored by Oncology Institute of Southern Switzerland.

Who is sponsoring NCT03966105?

NCT03966105 is sponsored by Oncology Institute of Southern Switzerland.

What drugs are being tested in NCT03966105?

Interventions in NCT03966105: HE and Congo red staining.

What condition does NCT03966105 study?

NCT03966105 studies Wild-type Transthyretin Amyloidosis.

Is NCT03966105 still recruiting?

NCT03966105 is currently completed. Last updated 27 March 2023.

Last reviewed 2023-03-27 · How we verify

NCT03966105

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevalence of Wild Type ATTR

Completed Last updated 27 March 2023

What this trial tests

trial testing HE and Congo red staining in Wild-type Transthyretin Amyloidosis in 94 participants. Completed in 31 October 2022.

Timeline

1 November 2019

Primary endpoint
31 October 2021

31 October 2022

Quick facts

Lead sponsor	Oncology Institute of Southern Switzerland
Status	Completed
Study type	OBSERVATIONAL
Enrollment	94
Start date	1 November 2019
Primary completion	31 October 2021
Estimated completion	31 October 2022
Sites	1 location across Switzerland

Drugs / interventions tested

HE and Congo red staining

Conditions studied

Wild-type Transthyretin Amyloidosis — all drugs for Wild-type Transthyretin Amyloidosis →

Sponsor

Oncology Institute of Southern Switzerland

Who can join

50 and older, any sex, with Wild-type Transthyretin Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, observational, single-centre, non-interventional study aiming at reporting the prevalence of ATTRwt in patients with lumbar spinal stenosis (LSS).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Suspicion, screening, and diagnosis of wild-type transthyretin amyloid cardiomyopathy: a systematic literature review.
Bay K, Gustafsson F, Maiborg M, Bagger-Bahnsen A, et al · · 2022 · cited 16× · PMID 35343098 · DOI 10.1002/ehf2.13884

Verify or expand the search:

Other Oncology Institute of Southern Switzerland trials

Trials by the same sponsor.

NCT07235098 — Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surge · NA · not yet recruiting
NCT05850182 — Lifestyle Intervention in Patients With Metastatic Prostate Cancer · NA · recruiting
NCT05748145 — Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 · Phase 2 · recruiting
NCT04549428 — Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC · Phase 2 · terminated
NCT04510766 — Tumor Molecular Profiling in Early Phase Clinical Trials · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03966105 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oncology Institute of Southern Switzerland
Last refreshed: 27 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03966105.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing